GAO Releases Annual Bid Protest Report to Congress for FY 2021, Identifies New “Top Ground” for Sustains
Client Alert | 3 min read | 11.18.21
On November 16, 2021, the U.S. Government Accountability Office (GAO) released its Annual Report on Bid Protests for Fiscal Year 2021. While GAO received slightly fewer protests in FY2021 than in the year prior, the overall protest “Effectiveness Rate”—meaning the percentage of cases in which the protester received relief, such as voluntary corrective action or a GAO sustain—remained relatively constant, at 48% (the rate has ranged from 44% to 51% in each of the past five years).
GAO’s Annual Report also provides a helpful summary of the most common grounds for sustained protests in the prior year. In FY2021, those grounds were as follows: (1) unreasonable technical evaluation; (2) flawed discussions; (3) unreasonable cost or price evaluation; and (4) unequal treatment. The inclusion of “flawed discussions” on the list is notable—it is the first time in recent history that discussions-based protest arguments have proven so successful. Though firm conclusions are difficult to draw based upon a single year’s data, this may indicate that GAO is taking a closer look—and holding agencies to a higher standard—at the propriety and fairness of discussions.
The chart below shows the top sustain grounds by year. As seen below, flawed technical evaluations and flawed cost/price evaluations continue to represent some of the most consistently successful grounds for sustains, meaning would-be protesters should consider whether they have a credible basis to make such arguments when weighing an award challenge.
Most Prevalent Sustain Grounds By Year | |||||||||
2021 |
2020 |
2019 |
2018 |
2017 |
2016 |
2015 |
2014 |
2013 | |
Flawed technical evaluation |
X |
X |
X |
X |
X |
X |
X | ||
Flawed cost/price evaluation |
X |
X |
X |
X |
X |
X |
X | ||
Flawed past performance evaluation |
X |
X |
X |
X | |||||
Flawed selection decision |
X |
X |
X |
X | |||||
Inadequate documentation |
X |
X |
X |
X | |||||
Unequal Treatment |
X |
X |
X |
X | |||||
Failure to follow evaluation criteria |
X |
X |
X | ||||||
Flawed solicitation |
X | ||||||||
Flawed discussions |
X |
Insights
Client Alert | 2 min read | 05.09.25
FDA Seeks Stakeholder Consultation on Prescription Drug User Fee Reauthorization
On May 8, the U.S. Food and Drug Administration (FDA) took steps to begin the process for reauthorizing the Prescription Drug User Fee Amendments (PDUFA) by announcing a public meeting to be held on July 14, 2025. The agency invited public stakeholders, including patient and consumer advocate groups, health care professionals, and scientific and academic experts to participate in the meeting and subsequent public meetings to consult on the PDUFA reauthorization.
Client Alert | 2 min read | 05.09.25
New SF-328 for Foreign Ownership, Control, and Influence Assessments Approved, Publication Imminent
Client Alert | 4 min read | 05.08.25
Client Alert | 4 min read | 05.07.25
